Although some accepted neoadjuvant therapy patients take the disadvantage for OS with these characters, such as age <65, patients of BCLC B stage, tumor size ≤5 cm, cirrhosis, high-level differentiation, positive MVI, and AFP <400. The gene discussed is AFP; the disease is neoplasm.